Randomized controlled trial of N-acetylcysteine versus l-carnitine among women with clomiphene-citrate-resistant polycystic ovary syndrome
- PMID: 31273783
- DOI: 10.1002/ijgo.12902
Randomized controlled trial of N-acetylcysteine versus l-carnitine among women with clomiphene-citrate-resistant polycystic ovary syndrome
Retraction in
-
Retraction.Int J Gynaecol Obstet. 2023 Sep;162(3):1130. doi: 10.1002/ijgo.14995. Epub 2023 Jul 8. Int J Gynaecol Obstet. 2023. PMID: 37422702
Abstract
Objective: To compare clinical and metabolic profiles between N-acetylcysteine and l-carnitine among women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS).
Methods: A randomized trial at Zagazig University between January 2017 and March 2018. Women with CC-resistant PCOS were allocated randomly to receive CC plus N-acetylcysteine or CC plus l-carnitine. The primary outcome was clinical pregnancy rate; secondary outcomes were ovulation rate and metabolic changes.
Results: Overall, 162 women completed the study (N-acetylcysteine group, n=82; l-carnitine group, n=80). After 3 months, there was no difference in pregnancy (P=0.15), ovulation (P=0.21), or spontaneous abortion (P=0.11) rates between the two groups. There was no significant decrease in BMI in either group (both P>0.05). There were improvements in menstrual pattern, follicle-stimulating hormone, luteinizing hormone, free testosterone, and insulin resistance markers in both groups (all P<0.05). An improvement in lipid profile was observed only in the l-carnitine group (P<0.001). N-Acetylcysteine treatment led to significantly greater improvement in free testosterone and insulin resistance parameters as compared with l-carnitine (all P<0.05).
Conclusions: Both N-acetylcysteine and l-carnitine were equally effective in improving pregnancy and ovulation rates among women with CC-resistant PCOS. However, N-acetylcysteine was superior in ameliorating insulin resistance and only l-carnitine improved lipid profile.
Trial registration: ClinicalTrials.gov: NCT03164421.
Keywords: Clomiphene citrate; N-acetylcysteine; Polycystic ovary syndrome; Resistance; l-Carnitine.
© 2019 International Federation of Gynecology and Obstetrics.
References
REFERENCES
-
- Hu L, Shen H, Wu QF, et al. Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer. Clin Exp Obstet Gynecol. 2014;41:288-292.
-
- Behboudi-Gandevani S, Ramezani Tehrani F, Rostami Dovom M, et al. Insulin resistance in obesity and polycystic ovary syndrome: Systematic review and meta-analysis of observational studies. Gynecol Endocrinol. 2016;32:343-353.
-
- Roe A, Hillman J, Butts S, et al. Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS. J Clin Endocrinol Metab. 2014;99:E841-E847.
-
- Cheraghi E, Mehranjani MS, Shariatzadeh MA, Esfahani MH, Ebrahimi Z. N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: An alternative to metformin. Reprod Fertil Dev. 2016;28:723-731.
-
- Salehpour S, Sene AA, Saharkhiz N, Sohrabi MR, Moghimian F. N-acetylcysteine as an adjuvant to clomiphene citrate for successful induction of ovulation in infertile patients with polycystic ovary syndrome. J Obstet Gynecol Res. 2012;38:1182-1186.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical